

24 February 2022

Maxwell

By email: fyi-request-17981-1813af09@requests.fyi.org.nz
Ref: H202117877

Dear Maxwell

Response to your request for official information

Thank you for your request under the Official Information Act 1982 (the Act) on 17 December 2021 for:

“The full meeting minutes from the 113th meeting of the Medicines Assessment Advisory Committee held on 14 December 2021 as outlined in the agenda (<https://www.medsafe.govt.nz/committees/maac/Agenda113-14Dec21.htm>).

Please include all relevant correspondence (supporting evidence, email/text communications, memorandum, etc) for any applications for consent to distribute a new medicine under Section 20 / 23 / 24 of the Medicines Act 1981 that were discussed during the meeting in question.”

Information within scope of your request is itemised in Appendix 1 of this letter and copies of the documents are enclosed. The table in Appendix 1 outlines the grounds under which I have decided to withhold information. Where information is withheld, this is noted in the document itself.

I trust this information fulfils your request. Under section 28(3) of the Act, you have the right to ask the Ombudsman to review any decisions made under this request. The Ombudsman may be contacted by email at: info@ombudsman.parliament.nz or by calling 0800 802 602.

Please note that this response, with your personal details removed, may be published on the Ministry website at: www.health.govt.nz/about-ministry/information-releases.

Yours sincerely



Chris James
Group Manager
Medsafe

Appendix 1: List of documents for release

#	Date	Document details	Decision on release
1	14 December 2021	Minutes of the 113 th meeting of the Medicines Assessment Advisory Committee	Some information withheld under section 9(2)(g)(ii) of the Act to maintain the effective conduct of public affairs through the protection of such Ministers, members of organisations, officers, and employees from improper pressure or harassment.
2	N/A	Medsafe Evaluation Report - Clinical	Some information withheld under the following sections of the Act: <ul style="list-style-type: none">• 9(2)(a) to protect the privacy of natural persons• 9(2)(b)(ii) where its release would likely unreasonably prejudice the commercial position of the person who supplied the information.
3	N/A	Medsafe Evaluation Report - Quality	Some information withheld under section 9(2)(b)(ii) of the Act.
4	N/A	Information supplied by Pfizer New Zealand in support of its application	Withheld in full under section 9(2)(b)(ii) of the Act..